Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …

Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …

Systemic lupus erythematosus (SLE) is a life-threatening autoimmune disease characterized
by adaptive immune system activation, formation of double-stranded DNA autoantibodies …

Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …

PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell …

Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …

The impact of bridging therapy (BT) on CD19-directed chimeric antigen receptor T-cell
(CD19CAR-T) outcomes in large B-cell lymphoma (LBCL) is poorly characterized. Current …

Summary CD19 CAR‐T have emerged as a new standard treatment for relapsed/refractory
(r/r) large B‐cell lymphoma (LBCL). CAR‐T real‐world (RW) outcomes published to date …

Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the
treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant …